Search

The production of electrolytic nickel includes the stage of leaching of captured firing nickel matte dust. The solutions formed during this process contain considerable amounts of Pb, which is difficult to extraction due to its low concentration upon the high-salt background. The sorption of lead from model solutions with various compositions by synthetic and natural titanosilicate sorbents (synthetic ivanyukite-Na-T (SIV), ivanyukite-Na-T, and AM-4) have been investigated. The maximal sorption capacity of Pb is up to 400 mg/g and was demonstrated by synthetic ivanyukite In solutions with the high content of Cl− (20 g/L), extraction was observed only with a high amount of Na (150 g/L). Molecular mechanisms and kinetics of lead incorporation into ivanyukite were studied by the combination of single-crystal and powder X-ray diffraction, microprobe analysis, and Raman spectroscopy. Incorporation of lead into natural ivanyukite-Na-T with the R3m symmetry by the substitution 2Na+ + 2O2− ↔ Pb2+ + □ + 2OH− leds to its transformation into the cubic P−43m Pb-exchanged form with the empirical formulae Pb1.26[Ti4O2.52(OH)1.48(SiO4)3]·3.32(H2O).

Titanosilicates comprise a broad class of materials with promising technological applications. The typical obstacle that restricts their industrial applicability is the high manufacturing cost due to the use of specific organotitanium precursors. We herein report a new approach to the synthesis of titanosilicates using an inexpensive inorganic precursor, ammonium titanyl sulfate (ATS or STA), (NH4)2TiO(SO4)2∙H2O. The latter is an intermediate in the processing of titanium-bearing concentrates produced from apatite-nepheline ores. In this paper, the new synthetic approach is exemplified by the microwave-assisted synthesis of IONSIVE-911, one of the most effective Cs-ion scavengers. The method can be modified to synthesize various titanosilicate compounds.

Background: Pulmonary involvement in systemic juvenile idiopathic arthritis (SJIA) is a rare but dangerous complication. The main risk factors are already known, such as macrophage activation syndrome, a refractory course of systemic juvenile arthritis, infusion reaction to interleukin 1 and/or interleukin 6 blockers, trisomy 21, and eosinophilia. However, information about respiratory system involvement (RSI) at the onset of SJIA is scarce. Our study aimed to evaluate the specific features of children with SJIA with RSI and their outcomes. Methods: In a single-center retrospective cohort study, we compared the information from the medical records of 200 children with SJIA according to ILAR criteria or SJIA-like disease (probable/possible SJIA) with and without signs of RSI (dyspnea, shortness of breath, pleurisy, acute respiratory distress syndrome, and interstitial lung disease (ILD)) at the disease onset and evaluated their outcomes (remission, development of chronic ILD, clubbing, and pulmonary arterial hypertension). Results: A quarter (25%) of the SJIA patients had signs of the RSI at onset and they more often had rash; hepato- and splenomegaly; heart (pericarditis, myocarditis), central nervous system, and kidney involvement; hemorrhagic syndrome; macrophage activation syndrome (MAS, 44.4% vs. 9.0%, p = 0.0000001); and, rarely, arthritis with fewer active joints, compared to patients without RSI. Five patients (10% from the group having RSI at the onset of SJIA and 2.5% from the whole SJIA cohort) developed fibrosing ILD. All of them had a severe relapsed/chronic course of MAS; 80% of them had a tocilizumab infusion reaction and further switched to canakinumab. Unfortunately, one patient with Down's syndrome had gone. Conclusion: Patients with any signs of RSI at the onset of the SJIA are required to be closely monitored due to the high risk of the following fibrosing ILD development. They required prompt control of MAS, monitoring eosinophilia, and routine checks of night oxygen saturation for the prevention/early detection of chronic ILD.

Background: Pediatric lupus nephritis (LN) is one of the most serious manifestations of systemic lupus erythematosus (SLE) in children, determining the outcomes of the disease. There are no standardized treatment protocols for pediatric LN, and the role of biologics has not yet been conclusively defined., Objectives: analyze the safety and efficacy of rituximab biosimilar BCD020 in pediatric patients with lupus nephritis., Methods: in a retrospective cohort study, the data from the case histories of 25 patients with LN (10 boys and 15 girls) with an onset age of 13 (9-16) years, who failed conventional non-biologic treatment or developed corticosteroid dependence/toxicity, were included. The diagnosis was made using Systemic Lupus International Collaborating Clinics (SLICC) classification criteria. Rituximab biosimilar BCD020 was prescribed in a dosage of 375 mg/m 2 every week (2-4 infusions) with repeated courses every 6-12 months (2-4 infusions) according to disease activity, B-cell depletion, and IgG levels. The dynamics of clinical and laboratory data, the activity of the disease by SLEDAI, and corticosteroid doses were assessed at the onset and during the rituximab trial., Results: The main patient's characteristics were: Pre-rituximab non-biologic conventional treatment included: cyclophosphamide 15 (60%), MMF 8 (32%), azathioprine 3 (12%), hydroxychloroquine 12 (48%), and pulse therapy of methylprednisolone followed by oral methylprednisolone 25 (100%). The time before rituximab was 7.0 (3.0-24.0) months, and the whole observation period was 7.0 (0; 24) months. The initial pre-rituximab treatment slightly reduced SLEDAI levels and the proportion of patients with LN. A significant reduction of SLEDAI, the anti-dsDNA level, proteinuria, hematuria, C4 complement, ESR, and the median corticosteroid dose by 80% from the initial value, as well as the proportion of patients without corticosteroids, was observed after rituximab administration. Two deaths were observed due to catastrophic SLE with macrophage activation syndrome, accompanied by a severe infection (invasive aspergillosis, n = 2). Three patients developed serious adverse events: pneumonia ( n = 2), transient agranulocytosis ( n = 1) after the third rituximab infusion, and meningitis, caused by Listeria monocytosis, after the first rituximab infusion. Eight patients received antibacterial treatment for different respiratory infections without hospital admissions., Conclusions: Rituximab biosimilar BCD020 showed effectiveness in LN, whereas previous non-biologic treatment was insufficiently effective. Randomized controlled trials are required to evaluate the efficacy and safety of rituximab and evaluate the benefits when compared with conventional SLE treatment.

The beneficial properties of algae make them perfect functional ingredients for food products. Algae have a high energy value and are a source of biologically active substances, proteins, fats, carbohydrates, vitamins, and macro- and microelements. They are also rich in polyunsaturated fatty acids, proteins, mycosporine-like amino acids, polysaccharides, polyphenols, carotenoids, sterols, steroids, lectins, halogenated compounds, polyketides, alkaloids, and carrageenans. Different extraction parameters are used depending on the purpose and the substances to be isolated. In this study, the following parameters were used: hydromodule 1:10 and an extraction duration of 1-2 h at the extraction temperature of 25-40 °C. A 30-50% solution of ethanol in water was used as an extractant. Algae extracts can be considered as potential natural sources of biologically active compounds with antimicrobial activity and antiviral properties. The content of crude protein, crude fat, and carbohydrates in U. Prolifera , C. racemosa var. peltata ( Chlorophyta ), S. oligocystum and S. fusiforme (SF-1) was studied. It was found that C. muelleri ( Bacillariophyta ), I. galbana ( Haptophyta ), and T. weissflogii ( Bacillariophyta ) contain about 1.9 times more omega-3 than omega-6 fatty acids. N. gaditana ( Ochrophyta ), D. salina ( Chlorophyta ), P. tricornutum ( Bacillaryophyta ) and I. galbana ( Haptophyta ) extracts showed inhibitory activity of varying intensities against E. coli or P. aeruginosa . In addition, algae and algae-derived compounds have been proposed to offer attractive possibilities in the food industry, especially in the meat sector, to evolve functional foods with myriad functionalities. Algae can increase the biological activity of food products, while the further study of the structure of compounds found in algae can broaden their future application possibilities.